The draft guidance from the US Food and Drug Administration released on 13 April, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry," seeks to increase the number of racial and ethnic participants that have historically been underrepresented in clinical trials.
The agency says its focus on having a broader spectrum of Americans enrolled in trials aligns with the Biden administration’s...






